ALK-Abelló A/S (AKBLF)

Market Cap	5.10B
Revenue (ttm)	768.66M
Net Income (ttm)	113.14M
Shares Out	n/a
EPS (ttm)	0.51
PE Ratio	45.11
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5
Average Volume	303
Open	19.90
Previous Close	20.59
Day's Range	19.90 - 19.90
52-Week Range	17.90 - 27.03
Beta	0.61
RSI	36.87
Earnings Date	May 6, 2025

About ALK-Abelló

ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including house dust mites, grass and tree pollen, ragweed, Japanese cedar, and food. It also provides consumer healt...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1923
• Employees: 2,753
• Stock Exchange: OTCMKTS
• Ticker Symbol: AKBLF

Financial Performance

In 2024, ALK-Abelló's revenue was 5.54 billion, an increase of 14.78% compared to the previous year's 4.82 billion. Earnings were 815.00 million, an increase of 67.70%.

Financial numbers in DKK